What does M-Pharma do?

M-Pharma is a pharmacy in Antwerpen. Private Limited, started on 27 July 2017, 1 establishment.

What is the address of M-Pharma?

The registered office of M-Pharma is located at Borsbeeksebrug 30, 2600 Antwerpen.

Is M-Pharma still active?

Yes. According to the CBE (29 October 2026) M-Pharma is active, legal situation “Normale toestand”, started on 27 July 2017.

Is M-Pharma registered on Peppol?

Yes, M-Pharma is registered on the Peppol network with ID 0208:0678937543.

What is the enterprise number of M-Pharma?

The enterprise number of M-Pharma is BE0678937543.

When was M-Pharma founded?

M-Pharma was founded on 27 July 2017.

Who are the directors of M-Pharma?

According to the 2025 annual accounts, the directors of M-Pharma are: AALBERTUS VAN DE WEERD, ERIK HEUTHORST, HUBERTUS VERHOEF.

Is M-Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 July 2017; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did M-Pharma make in 2025?

M-Pharma recorded a loss after taxes of € 11,138 in financial year 2025.

What is the revenue of M-Pharma?

As a small company, M-Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -5,098.

M-Pharma (Private Limited) - Antwerpen - BE0678937543

Dossier M-Pharma, printed on 29 October 2026 from databakkes.be/en/0678937543/m-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

M-Pharma from Antwerpen, company number BE0678937543, closed financial year 2025 with a result of € -11,138 after tax. For that financial year M-Pharma recorded a gross margin of € -5,098 and equity of € -242,824. Compared with financial year 2024, the result moved from € -264,618 to € -11,138. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 9, 2026.

What it is worth Caution

€ -242,824

▼ € 11,138 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -11,138

▲ 96 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,503

▲ 212% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1 million.

People and assets in 2025

Wage cost

€ 557

▼ € 127,060 vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,943

▼ 97% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2023	2023	2024	2025	Change 2024 → 2025
Revenue	€ 291,585 Revenue 2023: € 291,585 First fiscal year in the series	-	€ 257,939 Revenue 2024: € 257,939 First fiscal year in the series	-
Gross margin	€ -80,599 Gross margin 2023: € -80,599 First fiscal year in the series	€ -44,212 Gross margin 2023: € -44,212 ▲ € 36,387 vs 2023 (€ -80,599) Favourable step	€ -141,987 Gross margin 2024: € -141,987 ▼ € 97,775 vs 2023 (€ -44,212) Unfavourable step	€ -5,098 Gross margin 2025: € -5,098 ▲ € 136,889 vs 2024 (€ -141,987) Favourable step	▲ € 136,889
Profit after taxes	€ -133,875 Profit after taxes 2023: € -133,875 First fiscal year in the series	€ -105,927 Profit after taxes 2023: € -105,927 ▲ € 27,948 vs 2023 (€ -133,875) Favourable step	€ -264,618 Profit after taxes 2024: € -264,618 ▼ € 158,691 vs 2023 (€ -105,927) Unfavourable step	€ -11,138 Profit after taxes 2025: € -11,138 ▲ € 253,480 vs 2024 (€ -264,618) Favourable step	▲ € 253,480
Equity	€ 138,858 Equity 2023: € 138,858 First fiscal year in the series	€ 32,932 Equity 2023: € 32,932 ▼ 76% vs 2023 (€ 138,858) Unfavourable step	€ -231,686 Equity 2024: € -231,686 ▼ € 264,618 vs 2023 (€ 32,932) Unfavourable step	€ -242,824 Equity 2025: € -242,824 ▼ € 11,138 vs 2024 (€ -231,686) Unfavourable step	▼ € 11,138
Total debts	€ 58,690 Total debts 2023: € 58,690 First fiscal year in the series	€ 18,855 Total debts 2023: € 18,855 ▼ 68% vs 2023 (€ 58,690) Favourable step	€ 247,565 Total debts 2024: € 247,565 ▲ € 228,710 vs 2023 (€ 18,855) Unfavourable step	€ 243,772 Total debts 2025: € 243,772 ▼ 2% vs 2024 (€ 247,565) Favourable step	▼ 2%
Cash	€ 4,805 Cash 2023: € 4,805 First fiscal year in the series	€ 3,962 Cash 2023: € 3,962 ▼ 18% vs 2023 (€ 4,805) Unfavourable step	€ 1,122 Cash 2024: € 1,122 ▼ 72% vs 2023 (€ 3,962) Unfavourable step	€ 3,503 Cash 2025: € 3,503 ▲ 212% vs 2024 (€ 1,122) Favourable step	▲ 212%
Retained profit	€ -629,742 Retained profit 2023: € -629,742 First fiscal year in the series	€ -735,668 Retained profit 2023: € -735,668 ▼ € 105,927 vs 2023 (€ -629,742) Unfavourable step	€ -1,000,286 Retained profit 2024: € -1,000,286 ▼ € 264,618 vs 2023 (€ -735,668) Unfavourable step	€ -1,011,424 Retained profit 2025: € -1,011,424 ▼ € 11,138 vs 2024 (€ -1,000,286) Unfavourable step	▼ € 11,138
Balance sheet total	€ 197,549 Balance sheet total 2023: € 197,549 First fiscal year in the series	€ 51,787 Balance sheet total 2023: € 51,787 ▼ 74% vs 2023 (€ 197,549) Unchanged	€ 15,879 Balance sheet total 2024: € 15,879 ▼ 69% vs 2023 (€ 51,787) Unchanged	€ 5,948 Balance sheet total 2025: € 5,948 ▼ 63% vs 2024 (€ 15,879) Unchanged	▼ 63%
Employees (FTE)	-	0.9 Employees (FTE) 2023: 0.9 First fiscal year in the series	-	-

Key figures of M-Pharma, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 28 July 2027.

What happened to M-Pharma?

What happened at M-Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 9, 2026 New annual accounts for financial year 2025: loss of € 11,138. filed late Source: NBB ↗
2019 AALBERTUS VAN DE WEERD became a director. NBB
2019 ERIK HEUTHORST became a director. NBB
2019 HUBERTUS VERHOEF became a director. NBB
Jul 27, 2017 New establishment in Gent. KBO
Jul 27, 2017 Start of the company according to the CBE. KBO

In short

From € 133,875 loss in 2023 to € 11,138 loss in 2025.

Original PDFs at the National Bank ↗

Management

Mercurius Holding 100%

The stake of Mercurius Holding comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

M-Pharma

Behind M-Pharma are AALBERTUS VAN DE WEERD, ERIK HEUTHORST and HUBERTUS VERHOEF. The shares are held by Mercurius Holding (100%).

Directors

According to the 2025 annual accounts

AALBERTUS VAN DE WEERD

Manager

Also active at: Mercurius Holding

since 2019

ERIK HEUTHORST

Manager

Also active at: Mercurius Holding

since 2019

HUBERTUS VERHOEF

Manager

Also active at: Mercurius Holding

since 2019

Shareholders

Mercurius Holding

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Borsbeeksebrug 30

2600 Antwerpen

2.267.088.453

Prinses Clementinalaan 16

9000 Gent

Active since 27 July 2017

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.

All companies at this address →

Kuehne + Nagel

€ 563.7 million revenue · 2025

KRUIDVAT

€ 779.5 million revenue · 2025

Kuehne + Nagel Fulfillment

€ 20.7 million revenue · 2025

NACORA INSURANCE BROKERS

€ 1.1 million revenue · 2025

Teleperformance Belgium

€ 9.5 million gross margin · 2025

+3 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0678.937.543
VAT number: BE 0678.937.543
Registered office: Borsbeeksebrug 30, 2600 Antwerpen
Names & denominations: M-Pharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 July 2017
Peppol: Active · Active since 18 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

M-Pharma

Warning lights

Financials

What happened to M-Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions